BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15461466)

  • 1. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study.
    Meggio F; Pagano MA; Moro S; Zagotto G; Ruzzene M; Sarno S; Cozza G; Bain J; Elliott M; Deana AD; Brunati AM; Pinna LA
    Biochemistry; 2004 Oct; 43(40):12931-6. PubMed ID: 15461466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
    Sarno S; de Moliner E; Ruzzene M; Pagano MA; Battistutta R; Bain J; Fabbro D; Schoepfer J; Elliott M; Furet P; Meggio F; Zanotti G; Pinna LA
    Biochem J; 2003 Sep; 374(Pt 3):639-46. PubMed ID: 12816539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
    Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
    Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
    Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
    J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The raison d'être of constitutively active protein kinases: the lesson of CK2.
    Pinna LA
    Acc Chem Res; 2003 Jun; 36(6):378-84. PubMed ID: 12809523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2.
    Golub AG; Yakovenko OY; Bdzhola VG; Sapelkin VM; Zien P; Yarmoluk SM
    J Med Chem; 2006 Nov; 49(22):6443-50. PubMed ID: 17064064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Features and potentials of ATP-site directed CK2 inhibitors.
    Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
    Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
    Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
    Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells.
    Hessenauer A; Montenarh M; Götz C
    Int J Oncol; 2003 Jun; 22(6):1263-70. PubMed ID: 12738992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of protein kinase CK2 as a potent kinase of Epstein-Barr virus latent membrane protein 1.
    Chi LM; Yu JS; Chang YS
    Biochem Biophys Res Commun; 2002 Jun; 294(3):586-91. PubMed ID: 12056807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resorufin: a lead for a new protein kinase CK2 inhibitor.
    Sandholt IS; Olsen BB; Guerra B; Issinger OG
    Anticancer Drugs; 2009 Apr; 20(4):238-48. PubMed ID: 19177021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitory effect and kinetic analysis of sodium quercetin-7,4'-disulphate on recombinant human protein kinase CK2 holoenzyme].
    Liu XG; Liang NC; Liu W; She J; Mo LE
    Yao Xue Xue Bao; 2002 Mar; 37(3):165-8. PubMed ID: 12579753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect and its kinetic analysis of tyrphostin AG1478 on recombinant human protein kinase CK2 holoenzyme.
    Liu XG; Liang NC
    Acta Pharmacol Sin; 2002 Jun; 23(6):556-61. PubMed ID: 12060532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibitory effect of AG1109 on recombinant human protein kinase CK2 holoenzyme].
    Liu XG; Liang NC
    Ai Zheng; 2002 Feb; 21(2):153-7. PubMed ID: 12479065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
    Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
    Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
    Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
    Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight.
    Lolli G; Cozza G; Mazzorana M; Tibaldi E; Cesaro L; Donella-Deana A; Meggio F; Venerando A; Franchin C; Sarno S; Battistutta R; Pinna LA
    Biochemistry; 2012 Aug; 51(31):6097-107. PubMed ID: 22794353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').
    Sarno S; Reddy H; Meggio F; Ruzzene M; Davies SP; Donella-Deana A; Shugar D; Pinna LA
    FEBS Lett; 2001 May; 496(1):44-8. PubMed ID: 11343704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and exploitation of CK2 inhibitors.
    Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
    Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.